More than 90% of adults are latently infected with Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, a self-limiting lymphoproliferative disease characterized by extensive T cell activation. Reactivation of this herpesvirus during immunosuppression is often associated with oncogenesis. These considerations led us to analyze the early events that occur after exposure of the immune system to EBV. Strong major histocompatibility complex (MHC) class lI-dependent, but not MHC-restricted, T cell proliferation was observed in vitro in response to autologous, lytically infected EBV-transformed B cells. By measuring the appearance of the early activation marker CD69 on individual T cell V[3 subsets, we could demonstrate selective activation of human VI313 + T cells. This was confirmed with murine T cell hybridomas expressing various human BV genes. While EBV-Burkitt's lymphoma cells were nonstimulatory, they induced V]3-restricted T cell activation after EBV infection. EBV specific activation was also demonstrated in cord blood cells, excluding a recall-antigen response. Thus, all of the characteristics of a superantigen-stimulated response are seen, indicating that induction of the EBV lyric cycle is associated with the expression of a superantigen in B cells. A model is presented proposing a role for the superantigen in infection, latency, and oncogenesis. E BV has a strong tropism for B lymphocytes and has the capacity to activate them to proliferate continuously (reviewed in 1, 2). Exposure to EBV during childhood resuits in no symptoms or only limited symptoms. Infection during adolescence or early adulthood, however, can give rise to infectious mononucleosis (IM) l in ,-~ of cases. IM is a self-limiting lymphoproliferative disease characterized by virus shedding into the saliva, growth of infected B cells, and a massive expansion of nonspecific T cells. Initially, both CD4 + and CD8 + T cells are activated; however, later on, the response comprises mainly atypical CD8 + lymphoblastoid cells. Disease regression occurs gradually, manifested by a decrease in virus shedding as well as in the number of infected B cells. Presumably, this is mediated by virus-specific CTL (3).
Summary
More than 90% of adults are latently infected with Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, a self-limiting lymphoproliferative disease characterized by extensive T cell activation. Reactivation of this herpesvirus during immunosuppression is often associated with oncogenesis. These considerations led us to analyze the early events that occur after exposure of the immune system to EBV. Strong major histocompatibility complex (MHC) class lI-dependent, but not MHC-restricted, T cell proliferation was observed in vitro in response to autologous, lytically infected EBV-transformed B cells. By measuring the appearance of the early activation marker CD69 on individual T cell V[3 subsets, we could demonstrate selective activation of human VI313 + T cells. This was confirmed with murine T cell hybridomas expressing various human BV genes. While EBV-Burkitt's lymphoma cells were nonstimulatory, they induced V]3-restricted T cell activation after EBV infection. EBV specific activation was also demonstrated in cord blood cells, excluding a recall-antigen response. Thus, all of the characteristics of a superantigen-stimulated response are seen, indicating that induction of the EBV lyric cycle is associated with the expression of a superantigen in B cells. A model is presented proposing a role for the superantigen in infection, latency, and oncogenesis. E BV has a strong tropism for B lymphocytes and has the capacity to activate them to proliferate continuously (reviewed in 1, 2). Exposure to EBV during childhood resuits in no symptoms or only limited symptoms. Infection during adolescence or early adulthood, however, can give rise to infectious mononucleosis (IM) l in ,-~ of cases. IM is a self-limiting lymphoproliferative disease characterized by virus shedding into the saliva, growth of infected B cells, and a massive expansion of nonspecific T cells. Initially, both CD4 + and CD8 + T cells are activated; however, later on, the response comprises mainly atypical CD8 + lymphoblastoid cells. Disease regression occurs gradually, manifested by a decrease in virus shedding as well as in the number of infected B cells. Presumably, this is mediated by virus-specific CTL (3) .
EBV is a highly successful virus, which has evolved to inhabit and manipulate the immune system to its own advantage. The infection of antigen-presenting B cells, followed by a rapid activation of nonimmune T cells, led us to speculate that an EBV-associated superantigen might be influencing the immune response during the establishment of persistent infection.
1Abbreviations used in this paper: CBMC, cord blood mononuclear cells; IM, infectious mononucleosis; LCL, lymphoblastoid cell line; MMTV, murine mammary tumor virus; SEB, Staphylococcus enterotoxin B.
Superantigens are a class of pathogen-derived proteins that elicit a powerful T cell response, activating whole families oft cells with identical or related TCR V13 chains (reviewed in 4). Superantigens form a bridge between MHC class II molecules on APC and a region on the TCI/, V[3 chain outside of the unique antigen-binding domain. This bridging transduces a signal to the T cell as well as the APC, resulting in activation of both. The hallmarks ofa superantigen-induced T cell response are (a) a vigorous activation of primary T cells; (b) an MHC class II-dependent, but not MHC-restricted, recognition; and (c) a TCk V[3-restricted response. Exposure to superantigens in vivo resuits in skewing of the T cell repertoire, manifested either by amplification of particular T cell V[3 families, or deletion and/or anergy of specific subsets. A virally encoded superantigen could have irreversible, indirect effects on the human immune system by altering the response to pathogens, leading to disease or autoimmunity. An example is provided by the recent demonstration that the murine mammary tumor virus (MMTV) superantigen, Mls-1, predisposes mice to polyoma virus associated oncogenesis by deleting the cytotoxic T cells that control polyoma virus infection (5) .
Superantigens are evolutionarily conserved in certain pathogens, and it is presumed that they confer a selective advantage for the microbe. It has been well documented that stinmlation of the host's immune system by the prototypic viral superantigen, Mls, is essential for transmission of infectious MMTV (6) (7) (8) . Therefore, we set out to determine whether superantigen stimulation of the human immune system could likewise play a role in establishing persistent EBV infection and disease.
Materials and Methods
Proliferation Assays. Peripheral blood B cells from healthy adult volunteers were transformed to create lymphoblastoid cell lines (LCL), using viral supernatant from B95-8 cells, which produce a common laboratory strain of EBV (9, 10), or IM-1, an EBV strata isolated from an IM patient (a gift from M.A. Epstein, University of Oxford, England). LCL were stimulated with PMA (10 ng/ml) for 24 h to induce the lytic cycle, and were then treated with mitomycin C (100 b~g/ml) for 1 h to arrest cellular division. After extensive washing with PBS, LCL were added to freshly isolated autologous PBMC or allogeneic umbilical cord blood mononuclear cells (CBMC). PBMC and CBMC were isolated by density gradient separation on Ficoll-Paque Plus (Pharmacia, Uppsala, Sweden). All cells were cultured in complete RPMI media (GIBCO BRL, Gaithersburg, MD), supplemented with 10% FCS (Intergen, Purchase, NY), at 37~ with 5% CO2. Each assay was carried out in quadruplicate wells of a 96-well plate with 105 responders/well, using stimulator to responder ratios of 1:3 and 1:10. Stinmlation was compared to treatment with PHA (2 I.tg/ml). After an incubation period of 48 h, the cells were pulsed with [3H]thymidine (1 I.LCi/well) and harvested 8-12 h later to assess DNA synthesis as a measure of cellular proliferation. Similar assays were performed using as APC two EBV-Burkitt's lymphoma tumors, BL-2 and BL-41 (11), both before and subsequent to productive infection with B95-8 supernatant. APC were treated with PMA and mitomycin C and plated with allogeneic PBMC or CBMC at APC/responder ratios of 1:1, 1:3, or 1:10.
MHC Class II-blocking Experiments.
Proliferation assays were performed as described above, with the following modifications: before the addition of responder cells, in some of the wells, LCL were preincubated for 1 h with Dl-12 (80 btg/ml), an mAb that recognizes all HLA DR molecules (12) , or the same concentration of an isotypic control mAb 116-13.1, anti-lyt-2. The n~Ab remained in the cultures for the entire 72 h. Each assay was set up using autologous PBMC from adult donors as responders, and with a stimulator/responder ratio of 1:10. As a control, D1-12 (80 ~g/ml) was also added to PHA-treated cells. (18, 20) ; the hV[39 T cell hybrid DS3-A was constructed in a similar manner. They express the particular human VI3 gene in the context of nmrine Vcl and CD3 chains. It should be noted that the hV]313.3-1 hybridoma actually expresses VI313.6, according to a recent revision of the V]313 family nomenclature (21) . The hV[32 hybrid, TAL 8.1.9, has been previously described (22) T cell hybridomas were cultured for 24-36 h with PMAtreated B95-8 or IM-I LCL, or Burkitt's lymphoma cells, using 2 X 104 responders/well in quadruplicate wells of a 96-well plate, and stimulator/responder ratios of 1:1 or 1:3. As control, T cell hybridomas were stimulated by cross-linking the TCP, on anti-CD3-coated wells (145-2Cll ascites, diluted 1:3,000). Cell lysates were prepared by freezing the plates for at least 12 h, and IL-2 production was monitored in a bioassay using HT-2 indicator cells (24) .
CD69

Results
Peripheral Blood T Cells Proliferate in Response to Autologous, Lyrically It~ected EBV-transformed B Cells.
To investigate whether a vitally associated superantigen influences the establishment of persistent EBV infection, a classical T cell proliferation assay was performed. In this assay, lytically infected, EBV-transformed B LCL were used as APC, and autologous PBMC from healthy adult donors served as responders. This constituted an attempt to reproduce in vitro some of the initial events that occur during IM, leading to the massive T cell activation. It has not been possible to decipher these primary steps in vivo using IM patient blood samples, most likely because noticeable clinical symptonls Figure 1 . Proliferation of PBMC from healthy donors to autologous, lytically infected EBV-transformed B cells, and to an allogeneic EBV +, but not EBV-, Burkitt's lymphoma. B95-8 or IM-1 LCL, EBV-BL-2 cells, and B95-8-infected BL-2 cells were stimulated with PMA for 24 h to induce lytic viral replication and treated with mitomycin C for use as APC. Freshly isolated PBMC from donor 1 (A) and donor 2 (/3) were then added to autologous LCL or allogeneic BL-2 cells. Each assay was carried out using stimulator to responder ratios of 1:3 and 1:10. Stimulation with PHA was used as a positive control. 48 h proliferation was assessed by [3H]thymidine incorporation as a measure of DNA synthesis. Results were assessed in quadruplicate, and are expressed as the average cpm/well with the SD. often do not appear until after the disease has progressed to the lymphoproliferative stage. At that point, there is significant bystander T cell activation, resulting from cytokine production and the generally activated immune status, which can obscure EBV-specific T cell activation.
LCL were established in vitro by infection of B cells with two different strains of EBV: B95-8, a c o m m o n laboratory strain, and IM-1, a viral isolate derived from the peripheral blood of an IM patient. Since EBV is generally maintained in a latent form in LCL, we stimulated the cell lines for 24 h with the phorbol ester PMA, which induces the EBV lytic cycle and upregulates the production of viral proteins (25) . Figs. 1, A and B, depict representative results obtained with P B M C from two healthy unrelated adult donors. In both cases, 48 h proliferation, as assessed by [3H]thymidine incorporation, was demonstrated at levels comparable to the mitogen PHA. Maximum proliferation occurred at 72 h, although the absolute levels were not significantly higher (data not shown). To demonstrate that EBV is responsible for the strong proliferation, an EBVBurkitt's lymphoma line, BL-2, was P M A treated for use as APC. Although allogeneic, these cells were found to be nonsfimulatory or very weakly stimulatory at 48 h under identical conditions. Upon infection of the BL-2 cells with B95-8 EBV, strong proliferation was observed (Fig. 1, A and B) .
The Early Activation Marker CD69 Is Preferentially Expressed on V~813 T Cells after a 4-h Stimulation with Autologous B95-8 LCL.
The main characteristic of a superantigen is that it elicits a T C R Vl3-restricted response, resulting in a selective alteration of the T cell repertoire by either amplifying or deleting T cell clones that express the specific VI3 genes. If indeed the stimulation with autologous LCL is caused by the presence o f a superantigen, we would expect to selectively activate T cells of a particular TCt< VJ3 phenotype. To test this, we developed a novel means of defining Vl3-specific T cell activation; namely, we analyzed the appearance of the early activation marker CD69 (26, 27 ) on individual T cell V[3 subsets 4 h after stimulation. Cytokines, which are potent activators of bystander T cells, are produced between 5-6 h after stimulation; thus, we deliberately chose an earlier time point to minimize the induction of nonspecific T cell proliferation. Moreover, the absence of proliferation at this early time point guarantees detection ofa polyclonal response, excluding the readout of an oligoclonal expansion. This obviates the need for sequencing the VDJ region of numerous clones to establish polyclonality.
P B M C from the same two donors depicted in Fig. 1 were stimulated for 4 h with autologous B95-8 LCL or with PHA, The cells were then double stained with a PEconjugated anti-CD69 mAb and a panel of FITC-labeled anti-V[3 mAbs. The stimulated cells were analyzed by flow cytometry to assess the percentage of each VI3 subset that expressed CD69. As can be seen in Fig. 2 A, stimulation with LCL led in both donors to a significant increase in CD69 + cells in the VJ313 T cell subset. As expected, the percentage of CD69 + cells after stimulation with the mitogen P H A did not vary significantly between the VI3 subsets and was not significantly different from the overall percentage o f C D 6 9 + cells in unfractionated PBMC. These results suggest that EBV induces in B cells the expression o f a protein that is preferentially recognized by polyclonal V1313 T cells, implicating the presence of a superantigen. Similar results were obtained after stimulation with autologous IM-1 LCL, and with a third donor using autologous LCL as well (data not shown). After longer stimulation with P H A or LCL (>4 h), CD69 was expressed on a greater percentage of T cells (data not shown), probably because of activation of bystander T cells by the ensuing production of cytokines.
To ensure that the appearance of CD69 on particular V[3 subsets is truly indicative of superantigen activity, we analyzed the well-established superantigen response to SEB. The results obtained with PBMC of the same two donors are summarized in Fig. 2 B. The percentage ofCD69 + cells after SEB stimulation was significantly increased in the VJ312, VJ317, and VJ320 subsets, consistent with published reports using conventional methods of V[3 analyses (28) . The level of CD69 was highest on V~312 + cells, the subset shown to be deleted in an in vivo study after immunization with SEB (29) . On the other hand, the V~13 subset was not significantly elevated for CD69 staining after SEB treatment, indicating that the increased V[313 stinmlation in Fig. 2 A was specific for EBV LCL. Thus, our assay system is sensitive for detection of V{3-specific superantigen sfnmlation. It should be noted, however, that after 4 h incubation with SEB, CD69 expression was not significantly increased in the V~3a subset, despite the reported expansion of VJ33 T cells after long-term SEB stimulation (28). Since our assay relies on the specificity of the VI3 mAb used for the detection of T cell subsets, it is our opinion that screening for CD69 expression is useful only as an initial test for detection of V~ activation.
Murine T Cell Hybridomas Expressing Human V~I3.1, V~13.2, and V~13.6 Produce IL-2 in Response to B95-8 and IM-I LCL
The human VI313 fanny contains eight merebers, V{313.1-13.8, comprising a large portion of the overall T cell repertoire (GenBank/EMBL/DDBJ accession No. L36092). The anti-VJ313 mAb we have used, H131, was originally developed against the human BV13.1 gene product, expressed in a murine T cell hybridoma as a chimeric TCR with the murine Vet and CD3 chains (18) . The H131 mAb stains a relatively large percentage of peripheral blood cells from each donor tested (3-4.5%). Because the BV13 family members are highly homologous, it is difficult to rule out mAb cross-reactivity between the subfamilies.
To confirm the finding that LCL preferentially activate VI313 T cells, we tested murine T cell hybridomas expressing human VI313.1, VJ313.2, and V~313.6 chains, respectively (18, 20) . In addition, T cell hybrids expressing human V~2 (22) , VI33, VI38, VJ39, and V~17.1 were included in these experiments. These hybrids lack endogenous nmrine V~ genes, although the constant region and CD3 complex are of murine origin. The hV{32 and hVJ33 hybrids express human Vet as well, while all of the other hybrids express murine Vet chains. As can be seen in Fig. 3 A, the three VJ313 + T cell hybrids produced IL-2 after stimulation with either PMA-treated B95-8 or IM-l-derived LCL, but were only very weakly stimulated by latently infected LCL. On the other hand, the hVJ38 T hybrid was unreactive to the LCL, regardless of PMA treatment. Fig. 3 B shows that 
Proliferation to Antologous E B V L C L is M H C Class II Dependent, but Not Restricted.
P r e s e n t a t i o n o f all k n o w n superantigens to T cells is d e p e n d e n t o n expression o f M H C class II molecules. T o d e t e r m i n e w h e t h e r the T cell response against E B V -t r a n s of PBMC to autologous, lytically infected EBV LCL. Proliferation assay was performed as in Fig. 1 ; however, in some of the wells, LCL were preincubated with the mAb D1-12 or an isotypic control mAb 116-13.1, which remained in the cultures throughout the assay. Autologous B95-8 or IM-1 LCL were used as APC at a stimulator/responder ratio of 1:10. D1-12 added to PHA-treated cells did not affect stimulation.
sary for optimal stimulation, we have surmised that the activation is most likely caused by an EBV lytic gene. LCL are easily induced into the lytic cycle with phorbol ester (2) . Even in uninduced LCL, a small number of cells is present which spontaneously undergo lytic cycle viral replication. This number is significantly reduced in EBV + Burkitt's lymphoma lines (2) . Spontaneous lyric cycle gene expression, in combination with the alloresponse, could account for the weak stimulation induced by non-PMA-treated LCL o f the C B M C in Fig. 5 , as well as of the T cell hybrids in Fig. 3 A. Figure 5 . CBMC proliferate in response to lytically infected B95-8 and IM-1 LCL, and lytically infected EBV +, but not EBV , Burkitt's lymphomas. Fresh CBMC were stimulated with allogeneic, uninduced, and PMA-treated B95-8 and IM-1 LCL at stimulator/responder ratios of 1:3 and 1:10. CBMC were also stinmlated with allogeneic, PMA-treated EBV and B95-8-infected BL-2 and BL-41 cells at stinmlator/responder ratios of 1:1 and 1:3. The proliferation assay was performed as described in Fig. 1 .
cell proliferation, while mitogen-induced stimulation was unaffected. Preincubation with an isotypic control antibody, 116-13.1, did not block 48-h T cell proliferation.
T Cell Proliferation to EBV-transformed B Cells Is Not Caused by a Memory Response.
Since the vast majority of adults are EBV +, the massive proliferation induced by EBV-transformed LCL could be caused by a recall antigen response. To test this possibility, we used C B M C as responders in this assay because newborns are EBV-and cannot have memory T cells. As can be seen in Fig. 5 , C B M C vigorously proliferated at 48 h to allogeneic B95-8 and IM-1 LCL after PMA induction. Weak stimulation was observed in response to uninduced LCL. While the magnitude and the early kinetics o f the response pointed to the action of a superantigen rather than an alloresponse, the Burkitt lymphoma lines actually confirmed that the stimulation was caused by EBV. Strong proliferation was detected only after PMA treatment of B95-8-infected BL-2 and BL-41 cells. PMA treated EBV-BL cells were weakly stimulatory, as would be expected from the alloresponse, which is not optimal at 48 h.
It should be mentioned that the LCL in all of our assays induce higher levels of T cell stimulation than do the B95-8-infected Burkitt's lymphoma lines. In Fig. 5 , although the proliferation levels induced by all of the EBV + P M Atreated cells are comparable, the stimulator/responder ratios are 1:3 and 1:10 for the LCL, but 1:1 and 1:3 for the Burkitt's lymphomas. The difference in stimulation could be caused by several factors. LCL express higher levels than do most Burkitt's lymphoma lines of different cellular adhesion molecules, such as CD23, which possibly enhance T cell activation. In addition, since PMA treatment is neces-
Discussion
Taken together, the results presented here demonstrate the expression of a superantigen in EBV-transformed LCL and EBV + Burkitt's lymphomas that have been induced into the lytic cycle. The early activation of a large proportion of nonimmune T cells, combined with the fact that the stimulation is H L A -D R dependent, but not restricted, and the specific activation ofV[313 T cells, all support this conclusion. Furthermore, the response of the C B M C to EBV +, but not EBV Burkitt's lymphoma cells, exclude the possibility of an anamnestic recall antigen response because C B M C are by definition EBV-.
What are the possible advantages for EBV expressing a superantigen in infected B cells? We would predict that the superantigen is required for the establishment and/or the maintenance of persistent infection. The EBV latent genes have the capacity to directly induce B cell proliferation in vitro without T cell help, rendering superantigen stimulation superfluous. However, the site of viral persistence in vivo is a resting B cell that does not express the growthpromoting latent genes (30) . We suggest, therefore, that the role of superantigen-activated T cells is to provide signals necessary for the growth and survival of these latently infected B cells in vivo, possibly through C D 4 0 -C D 4 0 L interaction (see model in Fig 6) . This would replenish the pool of latently infected B cells, which does not decrease over time, but remains remarkably stable for years (30) . T cell regulatory signals might also induce differentiation of latently infected B cells, driving some of them to terminally differentiate, reactivate the virus, produce more superantigen, and thereby complete the cycle (Fig. 6) . This model proposes that viral replication is essential for viral persistence, not through reinfection of B ceils, but through superantigen driven activation of T ceils.
A role for T cells influencing EBV infection was suggested from earlier studies demonstrating that the spontaneous outgrowth of LCL in vitro from EBV-seropositive PBMC is more efficient in the presence of T cells (31) . This requirement for T cells is usually obscured by the seemingly converse finding that EBV-specific CTL, which arise later in culture, must be depleted because they will eliminate the newly generated LCL (32, 33) . Our model fits data obtained in vivo in SCID mice transplanted with EBV-seropositive human PBMC (34) (35) (36) spontaneously developed EBV-associated B cell lymphomas only when T cells were cotransferred, although the development of EBV-specific CTL limited tumor formation in some of the mice. Transplantation of highly purified B cells never yielded lymphomas, even in the presence of cytokines known to be secreted by activated T cells (35) , suggesting that a direct T cell-B cell interaction is requisite. The tumors that develop are a mixture of latently infected proliferating B cells, and terminally differentiated, lytically infected B cells that do not divide (37) . We would predict that the nondividing differentiated B cells provide an essential growth component for the growing tumor, namely superantigen-activated T cells. T cell signaling would promote B cell survival, allowing full latent gene expression, resulting in perpetual B cell proliferation. Simultaneously, T cells might push a fraction of cells to terminally differentiate, growth arrest, produce virus, and more superantigen (Fig. 6) . Eventually, some of the latently infected, rapidly dividing cells would accumulate mutations in cellular oncogenes such as myc, allowing them to lose the T cell dependence and become transformed. This hypothesis is in fact supported by the SCID/hu mouse model, since the tumors that arise in SCID mice after long periods of time no longer contain the fully differentiated, lytically infected cells (37) . The other side of the equation, for healthy humans, is the cytotoxic T cell response (38) . Persistent infection with EBV can thus be seen as a balance between the superantigen driven, T cell-dependent B cell growth, and the elimination oflatently infected proliferating B cells by CTL (Fig.  6) . The clinical symptoms of IM would arise as a result of the disruption of this balance. During IM, there is a rapid activation of both CD4 + and CD8 + T cells early after infection, presumably as a consequence of superantigen stimulation, mediated by the cytokine production of V[313 + T cells. A characteristically massive expansion ensues of nonspecific, atypically activated, apoptotic CD8 + T cells (39, 40) . The nonspecific activation of CD8 cells possibly delays the development of virus-specific CTL. This could be a mechanism for EBV to evade a specific immune response in establishing latency.
Paradoxically, EBV infection during childhood leads to seroconversion with limited or no clinical symptoms. The following scenario provides an explanation for this apparent incongruity: In adolescents exposed for the first time to this pathogen, the mature T cell pool is poised to mount a rapid superantigen response, while the development of virus-specific CTL requires priming, and is therefore only effective after an initial lag period. CTL priming might be further delayed by the superantigen-induced activation of nonspecific T cells, resulting in the symptoms oflM. Children, on the other hand, would predictably mount a suboptimal T cell response to the EBV superantigen, as inferred from murine studies, indicating an impaired immune response to viral superantigens in immature animals (41) . Thus, in children, the slower and weaker superantigen response would be balanced by the induction of EBV-specific CTL, preventing clinical manifestations. It is unclear whether IM represents an atypical immune response because the symptoms of IM are self-limiting and viral latency is established in both cases.
EBV reactivation in AIDS patients and transplant recipients often leads to the development of lymphomas and other lymphoproliferative diseases. Immunosuppression preferentially would affect the virus-specific memory CTL, compared to the superantigen-reactive primary T cells, disturbing the balance in the favor of the latter. The loss of CTL, which control the spread oflatently infected proliferating B cells, would lead to unregulated growth, favoring tumor development.
EBV has also been linked to the induction ofautoimmunity, especially in Sjogren's syndrome, which is associated with elevated levels of the virus in patients (42) . Of note are reports describing a significant increase in V[313 T cells in the lesions of patients with this autoimmune disease, indicative of the possible action of an EBV-associated superantigen (43) (44) (45) .
Recently, it has been suggested that the presence ofa superantigen in another herpesvirus, CMV, causes enhanced H1V-1 replication in V1312 T cells, which function as a reservoir for HIV-1 in infected patients (46) . It is plausible that EBV nfight play a similar role as CMV in AIDS, particularly since EBV infection is ubiquitous, and it has been reported that perturbations in the V[313 compartment occur in patients with HIV infection (47) . In addition, a recent report describes increased HIV-1 replication as a consequence of EBV lymphoma development in SCID mice transplanted with EBV-seropositive PBMC from HIV-I infected patients (48) .
Perhaps more importantly, we predict that some of the anergy and apoptosis of T cells occurring in HIV patients might actually be caused by activation-induced cell death, resulting as an indirect consequence of EBV superantigen stimulation, e.g., the increased cytokine environment. Furthermore, we speculate that the atypical, apoptotic CD8 + T cells, which are massively expanded during IM, constitute the same T cell subset that is augmented in HIV infection (49, 50) . In both diseases, elimination ofCD4 + T cells occurs, possibly caused in part by the nonspecific cytotoxic activity of these activated CD8 + T cells. It is conceivable that these cells arise during HIV infection as a result of superantigen expression after EBV reactivation by HIV-I Tat (51) . In support of our postulate, a correlation was recently found between T cell apoptosis in HIV-l-infected children and an increased burden of EBV (52) . Thus, interfering with the activation of V1313 T cells might have relevant clinical consequences.
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